Entourage Health Corp. (ETRGF) Q3 2024 Earnings Call Transcript Summary
Entourage Health Corp. (ETRGF) Q3 2024 Earnings Call Transcript Summary
Net revenue grew 9% year-over-year to $9.5 million, mainly led by growth in the bulk use channel.The following is a summary of the Entourage Health Corp. (ETRGF) Q3 2024 Earnings Call Transcript:
以下是Entourage Health企業(ETRGF) 2024年第三季度業績會實錄摘要:
Financial Performance:
財務表現：
Entourage Health Corp achieved a Q3 2024 total revenue of $13.6 million, an 11% year-over-year increase.
EBITDA increased 70% this quarter and 65% year-over-year, reflecting cost management and operational streamlining.
Net revenue grew 9% year-over-year to $9.5 million, mainly led by growth in the bulk use channel.
Gross profit before changes in fair value increased by 20%, totaling $2.9 million for Q3 2024.
Entourage Health企業取得了2024年第三季度總營業收入1360萬美元，同比增長11%。
本季度EBITDA增長了70%，同比增長65%，反映了成本管理和運營優化。
淨收入同比增長9%，達到950萬美元，主要由批發渠道增長所帶動。
在2024年第三季度，公允價值變動前的毛利潤增長了20%，達到290萬美元。
Business Progress:
業務進展：
Expanded sales channels and product diversification with 23 new SKUs across core brands.
Enhanced production efficiencies by automating pre-rolls, which now produces over 2 million per month.
Plans to launch Chromatica, Sour Grapefruit Haze Live Resin infused pre-rolls, and 20 by 0.5 gram Mega Packs in 2025.
Focusing on the medical cannabis market, specifically targeting veterans and aging populations with innovative patient-centric products.
擴大銷售渠道，核心品牌推出23款新SKU，實現產品多元化。
通過自動化捲菸的生產，提高了生產效率，目前每月產量超過200萬支。
計劃在2025年推出Chromatica、Sour Grapefruit Haze Live Resin注入式捲菸，以及20支0.5克的巨型包裝。
專注於醫療大麻市場，特別針對退伍軍人和老年人群體，提供創新的以患者爲中心的產品。
Opportunities:
機會：
High consumer demand for recently launched innovative formats like infused pre-rolls and value offerings.
Projected growth of Canada's medical cannabis sector, anticipated to surpass $1 billion by 2029.
近期推出的創新格式，如注入式捲菸和優惠產品，受到消費者的高需求。
預計加拿大醫療大麻板塊的增長，預計將在2029年超過10億美元。
Risks:
風險：
Lower medical revenue due to decreased patient renewal rates and reduced basket sizes.
Market forces pushing down sales prices while biomass costs are expected to rise in the short-term.
由於減少的患者續約率和減少的購買籃子大小，醫療營業收入下降。
市場力量推動銷售價格下降，而生物質成本預計短期內將上升。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情，請參閱IR網站。本文僅供投資者參考，不具有任何指導或推薦建議。
